Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis

Abstract Background Immune checkpoint inhibitors targeting PD-1/PD-L1 pathway demonstrated promising activities in variety of malignancies, however little is known regarding their efficacy in adults aged ≥65 years. Methods We conducted a systematic review and a study-level meta-analysis to explore e...

Full description

Bibliographic Details
Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Rawad Elias, Anita Giobbie-Hurder, Nadine Jackson McCleary, Patrick Ott, F. Stephen Hodi, Osama Rahma
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2018-04-01
Online Access:	http://link.springer.com/article/10.1186/s40425-018-0336-8

Similar Items

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
by: Dylan J. Martini, et al.
Published: (2017-08-01)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
by: Priyanka B. Subrahmanyam, et al.
Published: (2018-03-01)

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
by: F Stephen Hodi, et al.
Published: (2014-11-01)

Deciphering cardiotoxicity in PD-1/PD-L1 inhibitor treatment
by: Jacek Tabarkiewicz, et al.
Published: (2025-05-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
by: Matthias Pauschinger, et al.
Published: (2016-06-01)

Key differences between anti-PD-1/PD-L1 inhibitors
by: N. V. Zhukova, et al.
Published: (2022-06-01)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
by: Chao Cheng, et al.
Published: (2022-09-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022-03-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Stefania Oliva, et al.
Published: (2018-11-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
by: Vishakha Singh, et al.
Published: (2021-12-01)

Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
by: Adam P. Curnock, et al.
Published: (2021-10-01)

Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1/PD-L1 inhibitor therapy
by: Bo-Ya Li, et al.
Published: (2025-05-01)

Discovery of novel disulfide-containing PD-1/PD-L1 inhibitor with in vivo influenza therapeutic efficacy
by: Yoshiyuki Hirata, et al.
Published: (2025-09-01)

Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
by: Yanling Wang, et al.
Published: (2025-04-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review
by: Aleksandra S. Paderina, et al.
Published: (2024-07-01)

Optimizing PD-L1/PD-1 therapies: Immune checkpoint inhibitors in nasopharyngeal carcinoma
by: Madhan Krishnan, et al.
Published: (2024-12-01)

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)

Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
by: Domenico Ribatti, et al.
Published: (2024-07-01)

Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer
by: Xiaoyan Wan, et al.
Published: (2024-05-01)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
by: Faisal K. Alkholifi, et al.
Published: (2022-11-01)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
by: Yanting Zhou, et al.
Published: (2023-06-01)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
by: Shun-Long Ou, et al.
Published: (2023-04-01)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
by: Si-Yang Liu, et al.
Published: (2017-07-01)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
by: Hui Yang, et al.
Published: (2020-03-01)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
by: Dongxu Wang, et al.
Published: (2019-04-01)

Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
by: Zhansheng JIANG, et al.
Published: (2017-02-01)

Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with Extrahepatic Metastasis
by: Duan WB, et al.
Published: (2024-05-01)

Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis
by: Jie Yang, et al.
Published: (2024-08-01)

The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors
by: A. Boutros, et al.
Published: (2023-12-01)

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis
by: Tzu-Rong Peng, et al.
Published: (2023-11-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)

Efficacy of PD-1/PD-L1 and LAG-3 immune checkpoint inhibitors in the treatment of patients with solid tumor
by: Dahai Hu, et al.
Published: (2026-06-01)